1. Home
  2. DBD vs IRON Comparison

DBD vs IRON Comparison

Compare DBD & IRON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Diebold Nixdorf Incorporated

DBD

Diebold Nixdorf Incorporated

HOLD

Current Price

$70.57

Market Cap

3.0B

Sector

Technology

ML Signal

HOLD

Logo Disc Medicine Inc.

IRON

Disc Medicine Inc.

HOLD

Current Price

$66.92

Market Cap

2.6B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DBD
IRON
Founded
1859
2017
Country
United States
United States
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.0B
2.6B
IPO Year
2023
2020

Fundamental Metrics

Financial Performance
Metric
DBD
IRON
Price
$70.57
$66.92
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
11
Target Price
$90.00
$103.18
AVG Volume (30 Days)
301.8K
356.6K
Earning Date
04-30-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
677.27
N/A
EPS
0.14
N/A
Revenue
$3,805,700,000.00
N/A
Revenue This Year
$3.56
N/A
Revenue Next Year
$3.25
$283.52
P/E Ratio
$511.79
N/A
Revenue Growth
1.46
N/A
52 Week Low
$47.34
$40.00
52 Week High
$89.05
$99.50

Technical Indicators

Market Signals
Indicator
DBD
IRON
Relative Strength Index (RSI) 28.88 45.92
Support Level $68.51 $64.99
Resistance Level $70.84 $70.88
Average True Range (ATR) 3.05 3.13
MACD -1.26 -0.10
Stochastic Oscillator 0.00 20.50

Price Performance

Historical Comparison
DBD
IRON

About DBD Diebold Nixdorf Incorporated

Diebold Nixdorf Inc is engaged in providing software and hardware services for financial and retail industries. The customer segments of the company are Banking, which offers integrated solutions for financial institutions, and Retail, which offers solutions, software, and services that improve the checkout process for retailers. A majority of its revenue is generated from the Banking segment.

About IRON Disc Medicine Inc.

Disc Medicine Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for hematologic diseases. It aims to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for erythropoietic porphyrias (EPs), including erythropoietic protoporphyria (EPP), X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF) and anemia of chronic kidney disease (CKD); and DISC-3405 for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, the Company's preclinical programs include DISC-0998.

Share on Social Networks: